Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).

Inclusion Criteria:

• Subject's written informed consent obtained prior to any study related procedure;

• Male and female adults aged ≥ 18 and ≤ 75;

• Body mass index (BMI) within the range of 18.0 to 35.0 kg/m2 inclusive;

• Non-smokers or ex-smokers who smoked < 10 pack-years (pack-years = the number ofcigarette packs per day x the number of years) and stopped smoking > 1 year (6months for e-cigarettes) prior to screening;

• Diagnosis of asthma: physician-diagnosed asthma for at least

• 6 months and with diagnosis before the age of 50 years;

• Stable asthma therapy: a stable treatment with medium/high doses of inhaledcorticosteroids (ICS) + long-acting β-agonist (LABA) + long-acting muscarinicantagonist (LAMA) (fixed or free combination) or medium/high doses of ICS+LABA (fixed or free combination) for at least 4 weeks before screening (medium andhigh-dose ICS defined as BDP non-extrafine > 500-1000 μg and > 1000 μg respectively,or estimated clinical comparable dose).

• Subjects must have a cooperative attitude and the ability to be trained to usecorrectly the pMDI inhalers and e-Diary, to be able to read/write, to be able toperform the required outcomes measurements (e.g., technically acceptable spirometry,e-Diary completion) and the ability to understand the risks involved.

Exclusion Criteria:

• History of near fatal asthma, hospitalisation for asthma in intensive care unitwhich in the judgement of the Investigator may place the subject at undue risk,emergency room access for asthma in the previous 6 months before enrolment;

• Asthma exacerbation requiring systemic corticosteroids (SCS) or emergency roomadmission or hospitalisation within 4 weeks prior to study entry and/or during therun-in period (to be checked again prior to randomisation);

• Non-permanent asthma: exercise-induced, seasonal asthma (as the only asthma-relateddiagnosis) not requiring daily asthma control medecine